Equity Profile
Pre-Earnings Brief
Incyte Corp (INCY) is a biotechnology company focused on developing innovative therapies for cancer and other serious diseases. With a market cap of $19 billion, it plays a significant role in the health care sector, particularly in oncology, where it aims to improve patient outcomes through targeted treatments.
Earnings Per Share (EPS)
EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.
Revenue
Revenue figures provide insight into the company's sales performance and market demand for its products.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
3Q
EPS Beat Rate
63%
Avg EPS Surprise
-45.09%
Avg Stock Reaction
+0.51%
In the last quarter, Incyte reported an EPS of $1.80, exceeding expectations by nearly 10%. However, the stock experienced a decline of over 8% the following day, indicating market concerns despite the positive earnings surprise.
Management Promises & Guidance
Analysts expect Incyte to report solid earnings this quarter, with a consensus EPS of $1.37 and revenue of $1.2 billion. The market is cautiously optimistic following recent earnings surprises.
Bull Case
If Incyte beats EPS estimates and shows strong revenue growth, it could signal robust demand for its products, leading to a positive stock reaction.
Bear Case
Conversely, if the company misses its earnings targets or provides weak guidance, it may raise concerns about its growth prospects, leading to a negative market reaction.
Earnings Per Share (EPS)
$1.37EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.
Revenue
$1.2BRevenue figures provide insight into the company's sales performance and market demand for its products.
Expectations
The print will turn on these two things.
Q1
Will Incyte achieve an EPS of at least $1.37 this quarter?
This EPS figure is critical for maintaining investor confidence and could influence stock performance significantly.
Q2
What guidance will management provide regarding revenue growth for the upcoming quarters?
Future revenue guidance will be closely watched to assess the company's growth trajectory and market demand for its products.
Edge
Why consensus could be wrong
The consensus may underestimate the potential for Incyte's new drug pipeline to drive revenue growth beyond current expectations.
Supporting Evidence
Recent product launches have shown promising early sales figures, suggesting stronger demand than analysts anticipate.
Incyte's investment in R&D could yield breakthroughs that significantly enhance its market position.
The company's commitment to patient access initiatives may improve sales in underserved markets.
Key Risk
If Incyte's new drug sales exceed $300 million this quarter, it could challenge the current revenue forecasts.
Edge
Pre-commit to what would confirm each case.
This quarter's performance is pivotal as it will determine whether Incyte can sustain its growth momentum and meet market expectations.
Bull Confirmed If
An EPS of $1.50 or higher would confirm the bull case and indicate strong operational performance.
Bear Confirmed If
An EPS below $1.20 would support the bear case and raise concerns about the company's growth prospects.
Pre-Earnings Positioning
Implied Move
±4.2%
Historical Avg
±5.5%
The options market is pricing in a potential move of around 4.2% following the earnings report, indicating some uncertainty among investors.
Options are pricing ±2.7% while INCY has averaged ±5.5% over the last 8 prints — setup is pricing cheap.
30d HV
24.8%
Edge
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$1.8M
18,667 sh
1 insider
Net
$1.8M
Net selling
Most Active Insiders· 1 open-market trade
$1.8M
Net selling
Recent Transactions
Apr 17, 2026 · @ $96.50
18,667 sh
$1.8M
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
Preparation
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Incyte beats expectations, history suggests the stock could rise by about 0.94%, confirming a positive outlook.
In-Line / Cautious
If results are in line with expectations, the stock may experience muted movement as investors await further guidance.
Miss
A miss could lead to a decline of around 0.20%, reflecting investor disappointment and concerns about future performance.
Preparation
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
DOMINOS PIZZA INC